Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
ESK-001 by Alumis for Systemic Lupus Erythematosus: Likelihood of Approval
ESK-001 is under clinical development by Alumis and currently in Phase II for Systemic Lupus Erythematosus. According to GlobalData, Phase...
ESK-001 by Alumis for Plaque Psoriasis (Psoriasis Vulgaris): Likelihood of Approval
ESK-001 is under clinical development by Alumis and currently in Phase III for Plaque Psoriasis (Psoriasis Vulgaris). According to GlobalData,...
Risk adjusted net present value: What is the current valuation of Alumis's ESK-001?
ESK-001 is a small molecule commercialized by Alumis, with a leading Phase III program in Plaque Psoriasis (Psoriasis Vulgaris). According...